Palisade Bio Inc. buy Brookline Capital Management
Start price
13.05.25
/
50%
€0.34
Target price
13.05.26
€14.40
Performance (%)
-
End price
14.05.26
-
Summary
This prediction was cancelled by the user.Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Palisade Bio Inc. | - | - | - |
| iShares Core DAX® | -1.862% | 0.670% | 0.920% |
| iShares Nasdaq 100 | -3.322% | 4.989% | 33.716% |
| iShares Nikkei 225® | -2.299% | 6.129% | 52.955% |
| iShares S&P 500 | -1.313% | 3.399% | 24.674% |
Comments by Brookline_Capital_Ma for this prediction
In the thread Trading Palisade Bio Inc.
Die von Brookline_Capital_Ma gewählte maximale Laufzeit wurde überschritten
In the thread Palisade Bio Inc. diskutieren
Palisade Bio, Inc. (NASDAQ: PALI) had its "buy" rating re-affirmed by analysts at Brookline Capital Management. They now have a $16.00 price target on the stock.
Ratings data for PALI provided by MarketBeat